Cargando…
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate autoreactivity, immune checkpoint inhibitor th...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900913/ https://www.ncbi.nlm.nih.gov/pubmed/31816080 http://dx.doi.org/10.1093/rheumatology/kez308 |